SCHEMBL1834933

SCHEMBL1834933

COc1cc(C)ccc1P(c1ccccc1)c1ccc(C)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.48
CYP3A4 P08684 3/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 7/20 0.40
L3MBTL1 Q9Y468 6/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
HPGD P15428 3/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1833359 0.85 ACHE (0.60) ACHECYP3A4ALDH1A1MAPTL3MBTL1
SCHEMBL1834676 0.82 CA12 (0.48) CYP3A4ALDH1A1MAPTNPC1RAB9A
SCHEMBL10961316 0.81 ACHE (0.44) ACHECYP3A4ALDH1A1MAPTL3MBTL1
SCHEMBL1837860 0.81 CA12 (0.40) CYP3A4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1839614 0.81 FLT1 (0.41) CYP3A4ALDH1A1L3MBTL1KDM4ETDP1
SCHEMBL476857 0.79 CA1 (0.50) CYP3A4ALDH1A1L3MBTL1SMN1; SMN2HTT
SCHEMBL30992110 0.79 CA1 (0.50) CYP3A4ALDH1A1L3MBTL1SMN1; SMN2HTT
SCHEMBL17529737 0.78 CA1 (0.44) ACHEALDH1A1MAPTL3MBTL1NPC1
SCHEMBL26454178 0.77 CA12 (0.40) CYP3A4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL8459532 0.77 CA1 (0.48) CYP3A4ALDH1A1L3MBTL1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321244-B1 IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-21 EP disclosed
US-8558030-B2 Process for telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2013-10-15 US disclosed
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) 2011-06-09 US disclosed
EP-2321244-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2011-05-18 EP disclosed
WO-2010019360-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE HRH3, HRH4, TELO2 ACHE 4036/4885CYP3A4 1711/4885ALDH1A1 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.